Haleon PLC Sponsored ADR (H6D) Q2 2026 Earnings Report

The call conveyed more positive than negative developments: solid organic growth (3.1%) with sequential improvement, robust margin expansion (gross margin +140 bps; operating margin +120 bps), strong region/product performances (Oral Care, China, India, emerging markets) and continued investment behind digital and innovation. Key headwinds—weak Respiratory (notably cough & cold), regional softness in Europe and the Middle East, and some pricing pressure in Asia—are material but portrayed as cyclical or manageable through productivity and targeted reinvestment. Management maintained guidance (3%–5% organic growth) and expressed confidence in a stronger H2.

Management reiterated FY26 organic sales guidance of 3–5% (while maintaining a medium‑term ambition of 4–6%) and said H2 should be stronger than H1; Q2 organic sales were 3.1% (Q1 2.2%) with overall volume mix +1.4% and North America volume +2%, A&P in H1 grew 3.2% and sits at ~20.9% of sales with a planned step‑up in H2, and pricing is described as broadly in line with inflation and expected to be similar in H2. On margins, H1 constant‑currency operating margin improved 120 bps (gross margin +140 bps; FX +40 bps) and the company expects to deliver high‑single‑digit operating margin growth in H2, continue gross‑margin improvement while absorbing Middle East contract/hedge cost roll‑offs without exceptional pricing, and drive continued strong EPS growth after H1 EPS rose ~12%. They also reconfirmed operating‑model savings of GBP 175–200m in total, with roughly one‑third expected to fall in the current year.